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Résumé en
anglais
The aim of this study was to analyze retrospectively and critically the different steps
of the individual dose adjustment procedure employed in the concentration-
controlled (CC) versus fixed-dose trial Apomygre, which showed that mycophenolate
mofetil (MMF) dose adjustment using a limited sampling strategy significantly
reduced the risk of treatment failures and acute rejection in renal transplants at one
year posttransplantation.The number of AUCs performed during the study and
circumstances of collection, time of blood sampling, Bayesian mycophenolic acid
(MPA) area-under-the-curve (AUC) estimation procedures and physicians’ compliance
with MMF dose recommendations were retrospectively analyzed. 92% of AUCs
scheduled over the study were actually performed. Sampling times were very well
respected. Bayesian estimation of MPA exposure was done by the pharmacologists
locally in accordance with the protocol instructions and the AUC estimates obtained
were virtually all confirmed a posteriori. On the other hand, a second AUC estimated
by multiple linear regression could only be provided for 84% of the profiles and
showed a large overestimation with respect to Bayesian estimates for AUC values
between 10 and 55 mg h/L. In the CC arm, a very good physicians’ compliance was
observed (85%) and application of the dose recommendations led to higher values of
AUCs (42.1 ± 14.6 mg h/L versus 36.7 ± 16.3 mg h/L, p = 0.0035) and to more AUCs
in the target range (69% versus 56%, p = 0.0343) than when dose recommendations
were not applied. By analyzing in detail the feasibility criteria of MMF Bayesian dose
adjustment, this study highlighted the requirements for successful extrapolation of
the Apomygre trial results to routine practice: (i) respect of the PK sampling time-
windows; (ii) use of relevant tools for accurate drug exposure estimation and dose
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